Carregant...
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving (177)Lu-PSMA-617. Methods: 109 mCRPC patients treated with a median of 3 cycles of (177)Lu-PSMA-617 were included. Data were analyzed...
Guardat en:
| Publicat a: | Theranostics |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ivyspring International Publisher
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691377/ https://ncbi.nlm.nih.gov/pubmed/31410185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35759 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|